At 21.3x earnings with a Forward P/E of 13.1, the market is clearly pricing in a material earnings contraction from the current $14.9 EPS to the $10.22 estimate, suggesting skepticism about durability rather than enthusiasm for growth. A PEG of 1.4 implies only moderate growth relative to valuation, while the Altman Z-Score of 2.9 keeps the company out of distress territory but not in the highest safety bracket either. With a modest 1.1x sales multiple and 3.4x book, valuation is not stretched, yet the weak Piotroski F-Score of 3 and 2.30% ROE contradict the premium earnings multiple. This is a company priced for normalization, not expansion, and the market is cautiously discounting earnings risk rather than assigning a growth premium.